Targeted therapies for diarrhea-predominant irritable bowel syndrome

References

• SaitoYASchoenfeldPLockeGRIIIThe epidemiology of irritable bowel syndrome in North America: a systematic reviewAm J Gastroenterol2002971910191512190153
   PubMed Web of Science ®Google Scholar
• HunginAPChangLLockeGRDennisEHBarghoutVIrritable bowel syndrome in the United States: prevalence, symptom patterns and impactAliment Pharmacol Ther2005211365137515932367
   PubMed Web of Science ®Google Scholar
• American College of Gastroenterology Task Force on Irritable Bowel SyndromeAn evidence-based position statement on the management of irritable bowel syndromeAm J Gastroenterol2009104Suppl 1S1S35
   Google Scholar
• AndrewsEBEatonSCHollisKAPrevalence and demographics of irritable bowel syndrome: results from a large Web-based surveyAliment Pharmacol Ther20052293594216268967
   PubMed Web of Science ®Google Scholar
• International Foundation for Functional Gastrointestinal DisordersIBS in the Real World SurveySummary findings. Website2007 Available from: http://aboutconstipation.org/pdfs/IBSRealWorld.pdfAccessed February 3, 2012
   Google Scholar
• El-SeragHBOldenKBjorkmanDHealth-related quality of life among persons with irritable bowel syndrome: a systematic reviewAliment Pharmacol Ther2002161171118512030961
   PubMed Web of Science ®Google Scholar
• GralnekIMHaysRDKilbourneANaliboffBMayerEAThe impact of irritable bowel syndrome on health-related quality of lifeGastroenterology200011965466010982758
   PubMed Web of Science ®Google Scholar
• DrossmanDACamilleriMMayerEAWhiteheadWEAGA technical review on irritable bowel syndromeGastroenterology20021232108213112454866
   PubMed Web of Science ®Google Scholar
• SikanderARanaSVPrasadKKRole of serotonin in gastrointestinal motility and irritable bowel syndromeClin Chim Acta2009403475519361459
   PubMed Web of Science ®Google Scholar
• GershonMDTackJThe serotonin signaling system: from basic understanding to drug development for functional GI disordersGastroenterology200713239741417241888
   PubMed Web of Science ®Google Scholar
• DunlopSPColemanNSBlackshawEAbnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndromeClin Gastroenterol Hepatol2005334935715822040
   PubMed Web of Science ®Google Scholar
• AtkinsonWLockhartSWhorwellPJKeevilBHoughtonLAAltered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndromeGastroenterology2006130344316401466
   PubMed Web of Science ®Google Scholar
• ClarkeGQuigleyEMCryanJFDinanTGIrritable bowel syndrome: towards biomarker identificationTrends Mol Med20091547848919811951
   PubMed Web of Science ®Google Scholar
• SaadRJCheyWDRecent developments in the therapy of irritable bowel syndromeExpert Opin Investig Drugs200817117130
   PubMed Web of Science ®Google Scholar
• MayerEAClinical practice. Irritable bowel syndromeN Engl J Med20083581692169918420501
   PubMed Web of Science ®Google Scholar
• LacyBEWeiserKDe LeeRReview: the treatment of irritable bowel syndromeTherap Adv Gastroenterol20092221238
   PubMedGoogle Scholar
• GorardDALibbyGWFarthingMJInfluence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndromeAliment Pharmacol Ther199481591668038347
   PubMed Web of Science ®Google Scholar
• CrowellMDThe role of serotonin in the pathophysiology of irritable bowel syndromeAm J Manag Care20017SupplS252S26011474910
   PubMed Web of Science ®Google Scholar
• BakerDERationale for using serotonergic agents to treat irritable bowel syndromeAm J Health Syst Pharm20056270071115790796
   PubMed Web of Science ®Google Scholar
• LinHCSmall intestinal bacterial overgrowth: a framework for understanding irritable bowel syndromeJAMA200429285285815316000
   PubMed Web of Science ®Google Scholar
• PimentelMChowEJLinHCNormalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled studyAm J Gastroenterol20039841241912591062
   PubMed Web of Science ®Google Scholar
• PimentelMLemboACheyWDRifaximin therapy for patients with irritable bowel syndrome without constipationN Engl J Med2011364223221208106
   PubMed Web of Science ®Google Scholar
• MayerEABermanSDerbyshireSWThe effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patientsAliment Pharmacol Ther2002161357136612144587
   PubMed Web of Science ®Google Scholar
• HoughtonLAFosterJMWhorwellPJAlosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteersAliment Pharmacol Ther20001477578210848662
   PubMed Web of Science ®Google Scholar
• JohansonJFOptions for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapiesNeurogastroenterol Motil20041670171115601419
   PubMed Web of Science ®Google Scholar
• Lotronex^® (alosetron hydrochloride) tablets [package insert]San Diego, CAPrometheus Laboratories Inc2010
   Google Scholar
• FordACTalleyNJSchoenfeldPSQuigleyEMMoayyediPEfficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysisGut20095836737819001059
   PubMed Web of Science ®Google Scholar
• RajagopalanMKurianGJohnJSymptom relief with amitriptyline in the irritable bowel syndromeJ Gastroenterol Hepatol1998137387419715427
   PubMed Web of Science ®Google Scholar
• VahediHMeratSMomtahenSClinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndromeAliment Pharmacol Ther20082767868418248658
   PubMed Web of Science ®Google Scholar
• GreenbaumDSMayleJEVanegerenLEEffects of desipramine on irritable bowel syndrome compared with atropine and placeboDig Dis Sci1987322572663545719
   PubMed Web of Science ®Google Scholar
• DrossmanDATonerBBWhiteheadWECognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disordersGastroenterology2003125193112851867
   PubMed Web of Science ®Google Scholar
• Abdul-BakiHEl HajjIIElzahabiLA randomized controlled trial of imipramine in patients with irritable bowel syndromeWorld J Gastroenterol2009153636364219653341
   PubMed Web of Science ®Google Scholar
• TalleyNJKellowJEBoycePTennantCHuskicSJonesMAnti-depressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trialDig Dis Sci20085310811517503182
   PubMed Web of Science ®Google Scholar
• MillerVHopkinsLWhorwellPJSuicidal ideation in patients with irritable bowel syndromeClin Gastroenterol Hepatol200421064106815625650
   PubMed Web of Science ®Google Scholar
• KuikenSDTytgatGNBoeckxstaensGEThe selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled studyClin Gastroenterol Hepatol2003121922815017494
   PubMed Web of Science ®Google Scholar
• TabasGBeavesMWangJFridayPMardiniHArnoldGParoxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trialAm J Gastroenterol20049991492015128360
   PubMed Web of Science ®Google Scholar
• MasandPSPaeCUKrulewiczSA double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndromePsychosomatics200950788619213976
   PubMed Web of Science ®Google Scholar
• TackJBroekaertDFischlerBVan OudenhoveLGeversAMJanssensJA controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndromeGut2006551095110316401691
   PubMed Web of Science ®Google Scholar
• MarshallJKThabaneMGargAXClarkWFSalvadoriMCollinsSMIncidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysenteryGastroenterology200613144545016890598
   PubMed Web of Science ®Google Scholar
• FordACSpiegelBMTalleyNJMoayyediPSmall intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysisClin Gastroenterol Hepatol200971279128619602448
   PubMed Web of Science ®Google Scholar
• MalinenERinttilaTKajanderKAnalysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCRAm J Gastroenterol200510037338215667495
   PubMed Web of Science ®Google Scholar
• FrissoraCLCashBDReview article: the role of antibiotics vs conventional pharmacotherapy in treating symptoms of irritable bowel syndromeAliment Pharmacol Ther2007251271128117509095
   PubMed Web of Science ®Google Scholar
• PimentelMChowEJLinHCEradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndromeAm J Gastroenterol2000953503350611151884
   PubMed Web of Science ®Google Scholar
• PimentelMParkSMirochaJKaneSVKongYThe effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trialAnn Intern Med200614555756317043337
   PubMed Web of Science ®Google Scholar
• YuDCheesemanFVannerSCombined orocaecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects orocaecal transit, not small intestinal bacterial overgrowth in patients with IBSGut20116033434021112950
   PubMed Web of Science ®Google Scholar
• SpiegelBMRQuestioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspectiveClin Gastroenterol Hepatol2011946146921397724
   PubMed Web of Science ®Google Scholar
• WaltersBVannerSJDetection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controlsAm J Gastroenterol20051001566157015984983
   PubMed Web of Science ®Google Scholar
• HalvorsonHASchlettCDRiddleMSPostinfectious irritable bowel syndrome – a meta-analysisAm J Gastroenterol20061011894189916928253
   PubMed Web of Science ®Google Scholar
• KassinenAKrogius-KurikkaLMakivuokkoHThe fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjectsGastroenterology2007133243317631127
   PubMed Web of Science ®Google Scholar
• QuigleyEMWhat is the evidence for the use of probiotics in functional disorders?Curr Gastroenterol Rep20081037938418627649
   PubMedGoogle Scholar
• ShararaAIAounEAbdul-BakiHMounzerRSidaniSElhajjIA randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulenceAm J Gastroenterol200610132633316454838
   PubMed Web of Science ®Google Scholar
• MoayyediPDuffettSMasonSBrownJAxonATRThe influence of antibiotics on irritable bowel syndrome: a randomised controlled trial [abstract T1487]Gastroenterology2002122Suppl 4A465
   Web of Science ®Google Scholar
• JiangZDDuPontHLRifaximin: in vitro and in vivo antibacterial activity – a reviewChemotherapy200551Suppl 1677215855749
   PubMed Web of Science ®Google Scholar
• LemboAZakkoSFFerreiraNLRifaximin for the treatment of diarrhea associated irritable bowel syndrome: short term treatment leading to long term sustained response [abstract T1390]Gastroenterology2008134Suppl 1A545
   Google Scholar
• RingelYPalssonOSZakkoSFPredictors of clinical response from a hase 2 multi-center efficacy trial using rifaximin, a gut-selective, non-absorbed antibiotic for the treatment of diarrhea associated irritable bowel syndrome [abstract T1411]Gastroenterology2008134Suppl 1A550
   Google Scholar
• PimentelMRingelYBrooksCBorteyEForbesWSeverity of irritable bowel syndrome-related symptoms predicts clinical response to the nonsystemic antibiotic rifaximin [abstract P1065]Presented at the 73rd annual meeting of the American College of GastroenterologyOctober 3–8, 2008Orlando, FL
   Google Scholar
• CheyWDTalleyNJLemboAYuABorteyERifaximin significantly improves quality of life versus placebo in patients with diarrhea–predominant irritable bowel syndrome [abstract P691]Presented at the 73rd annual meeting of the American College of GastroenterologyOctober 3–8, 2008Orlando, FL
   Google Scholar
• PimentelMLemboACheyWDRifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American phase 3 trials (Target 1 and Target 2) [abstract 475i]Gastroenterology2010138S-64S-65
   Web of Science ®Google Scholar
• Clinicaltrials.gov Identifier: NCT00731679Rifaximin TID for non-constipation irritable bowel syndrome (IBS) (Target 1)National Institutes of Health2009 Available from: http://clinicaltrials.gov/ct2/show/NCT000731679?term=Rifaximin&rank=12Accessed February 3, 2012
   Google Scholar
• Clinicaltrials.gov identifier: NCT00724126Rifaximin 3 times/day for non–constipation IBS (Target 2)US National Institutes of Health2009 Available from: http://clinicaltrials.gov/ct2/show/NCT00724126?term=rifaximin&rank=11Accessed February 3, 2012
   Google Scholar
• DrossmanDATreatment for bacterial overgrowth in the irritable bowel syndromeAnn Intern Med200614562662817043344
   PubMed Web of Science ®Google Scholar
• TackJAntibiotic therapy for the irritable bowel syndromeN Engl J Med2011364818221208112
   PubMed Web of Science ®Google Scholar
• Salix receives anticipated FDA complete response letter on XIFAXAN^® 500 mg tablets Non-C IBS Supplemental New Drug ApplicationSalix Pharmaceuticals, Inc2011 Available from: http://www.salix.com/news-media/news/index/salix-receives-anticipated-fda-complete-response-letter-on-xifaxan®-550-mg-tablets-non-c-ibs-supplemental-new-drug-application.aspxAccessed February 3, 2012
   Google Scholar
• ViramontesBECamilleriMMcKinzieSPardiDSBurtonDThomfordeGMGender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndromeAm J Gastroenterol2001962671267611569693
   PubMed Web of Science ®Google Scholar
• DelvauxMRole of visceral sensitivity in the pathophysiology of irritable bowel syndromeGut200251Suppl 1i67i7112077070
   PubMed Web of Science ®Google Scholar
• CamilleriMMayerEADrossmanDAImprovement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonistAliment Pharmacol Ther1999131149115910468696
   PubMed Web of Science ®Google Scholar
• BardhanKDBodemarGGeldofHA double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndromeAliment Pharmacol Ther200014233410632642
   PubMed Web of Science ®Google Scholar
• CamilleriMNorthcuttARKongSDukesGEMcSorleyDMangelAWEfficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trialLancet20003551035104010744088
   PubMed Web of Science ®Google Scholar
• CamilleriMCheyWYMayerEAA randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndromeArch Intern Med20011611733174011485506
   PubMed Web of Science ®Google Scholar
• LemboTWrightRABagbyBAlosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndromeAm J Gastroenterol2001962662267011569692
   PubMed Web of Science ®Google Scholar
• WatsonMELaceyLKongSAlosetron improves quality of life in women with diarrhea-predominant irritable bowel syndromeAm J Gastroenterol20019645545911232690
   PubMed Web of Science ®Google Scholar
• WolfeSGCheyWYWashingtonMKTolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patientsAm J Gastroenterol20019680381111280555
   PubMed Web of Science ®Google Scholar
• OldenKDeGarmoRGJhingranPPatient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndromeAm J Gastroenterol2002973139314612492201
   PubMed Web of Science ®Google Scholar
• CheyWDCheyWYHeathATLong-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndromeAm J Gastroenterol2004992195220315555002
   PubMed Web of Science ®Google Scholar
• LemboAJOldenKWAmeenVZGordonSLHeathATCarterEGEffect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trialsClin Gastroenterol Hepatol2004267568215290660
   PubMed Web of Science ®Google Scholar
• ChangLAmeenVZDukesGEMcSorleyDJCarterEGMayerEAA dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBSAm J Gastroenterol200510011512315654790
   PubMed Web of Science ®Google Scholar
• KrauseRAmeenVGordonSHA randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBSAm J Gastroenterol20071021709171917509028
   PubMed Web of Science ®Google Scholar
• NicandroJPAShinPShringarpureRChuangEPanHAlosetron is associated with improvements in treatment satisfaction and quality of life [abstract M1058]Presented at Digestive Disease Week 2010May 1–5, 2010New Orleans, LA
   Google Scholar
• MillerDBennettLHollisKTennisPCookSAndrewsEA patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programmeAliment Pharmacol Ther20062486987816918892
   PubMed Web of Science ®Google Scholar
• ChangLCheyWDHarrisLOldenKSurawiczCSchoenfeldPIncidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance dataAm J Gastroenterol20061011069107916606352
   PubMed Web of Science ®Google Scholar
• ChangLTongKAmeenVIschemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidencesAm J Gastroenterol201010586687520197759
   PubMed Web of Science ®Google Scholar
• ChangLKahlerKHSarawateCQuimboRKralsteinJAssessment of potential risk factors associated with ischaemic colitisNeurogastroenterol Motil200820364217919313
   PubMed Web of Science ®Google Scholar
• ColeJACookSFSandsBEAjeneANMillerDPWalkerAMOccurrence of colon ischemia in relation to irritable bowel syndromeAm J Gastroenterol20049948649115056090
   PubMed Web of Science ®Google Scholar
• LongstrethGFYaoJFDiseases and drugs that increase risk of acute large bowel ischemiaClin Gastroenterol Hepatol20108495419765672
   PubMed Web of Science ®Google Scholar
• SinghGMithalATriadafilopoulosGPatients with irritable bowel syndrome have a high-risk of developing ischemic colitis [abstract 349]Gastroenterology2004126A41
   Web of Science ®Google Scholar
• SuhDCKahlerKHChoiISShinHKralsteinJShetzlineMPatients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitisAliment Pharmacol Ther20072568169217311601
   PubMed Web of Science ®Google Scholar
• WalkerAMBohnRLCaliCCookSFAjeneANSandsBERisk factors for colon ischemiaAm J Gastroenterol2004991333133715233674
   PubMed Web of Science ®Google Scholar
• LewisJHThe risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapiesDrug Saf20113454556521663331
   PubMed Web of Science ®Google Scholar
• RingelYCarrollIMAlterations in the intestinal microbiota and functional bowel symptomsGastrointest Endosc Clin North Am200919141150vii
   PubMedGoogle Scholar
• CorazzaGRMenozziMGStrocchiAThe diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testingGastroenterology1990983023092295385
   PubMed Web of Science ®Google Scholar
• RiordanSMMcIverCJWalkerBMDuncombeVMBolinTDThomasMCThe lactulose breath hydrogen test and small intestinal bacterial overgrowthAm J Gastroenterol199691179518038792701
   PubMed Web of Science ®Google Scholar
• PosserudIStotzerPOBjornssonESAbrahamssonHSimrenMSmall intestinal bacterial overgrowth in patients with irritable bowel syndromeGut20075680280817148502
   PubMed Web of Science ®Google Scholar
• ChanWWFeldmanNBurakoffRRisk factors for incomplete antibiotic treatment response in small intestinal bacterial overgrowth [abstract T1057]Presented at Digestive Disease Week 2010May 1–5, 2010New Orleans, LA
   Google Scholar
• US Food and Drug AdministrationGuidance for industryIrritable bowel syndrome–clinical evaluation of products for treatment [draft]US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research2010 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM205269.pdfAccessed February 3, 2012
   Google Scholar